Speaker
Dr
Olav Benjamin Ryan
(Bayer AS)
Description
Targeted thorium conjugates (TTCs) represent a new class of therapeutic radiopharmaceuticals for the targeted alpha therapy (TAT) of cancer. Cell surface glycoprotein mesothelin is highly expressed in many human cancers. Mesothelin targeted thorium-227 conjugate (MSLN-TTC, BAY 2287411), comprising a mesothelin targeted antibody (MSLN-Ab), covalently attached to 3,2-HOPO chelator, enabling specific complexation and delivery of the alpha particle emitter thorium-227 (227Th) to tumor cells, is currently in a phase 1 clinical trial (NCT03507452). 3,2-HOPO systems are also very efficient chelators for zirconium-89 and it has therefore been suggested that positron emission tomography (PET) imaging provides a useful surrogate for understanding 227Th radio-immunotherapy. Hence, we describe the radiolabeling of the conjugated MSLN-Ab conjugate with the PET isotope zirconium-89 (89Zr) and show data from a biodistribution study comparing both thorium and zirconium conjugates.
| Email Address | olav.ryan@bayer.com |
|---|---|
| Presentation Type | Poster |
Primary author
Dr
Olav Benjamin Ryan
(Bayer AS)
Co-authors
Dr
Alan Cuthbertson
(Bayer AS)
Dr
Alexander Kristian
(Bayer AS)
Dr
Baard Indrevoll
(Bayer AS)
Dr
Jenny Karlsson
(Bayer AS)
Dr
Roger M Bjerke
(Bayer AS)
Dr
Urs B Hagemann
(Bayer AG)
